Update in recent clinical trials in heart failure

Area of Science:

• Cardiology
• Clinical Trials
• Translational Medicine

Background:

• Heart failure (HF) is a significant and growing global health concern.
• Despite advancements, HF continues to have high mortality and morbidity rates.
• Novel therapeutic strategies are crucial for improving HF management.

Purpose of the Study:

• To review recent clinical trials in heart failure.
• To highlight practice-changing treatment strategies.
• To provide practical insights for clinicians and researchers.

Main Methods:

• Review of recent landmark clinical trials in heart failure.
• Synthesis of evidence on novel therapeutic interventions.
• Focus on trials impacting HF prevention and treatment.

Main Results:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise in HF prevention for diabetic patients with cardiovascular risk.
• Targeted therapies for transthyretin cardiac amyloidosis may halt disease progression.
• Intravenous iron therapy benefits patients with iron deficiency anemia and chronic systolic HF.
• Angiotensin receptor blocker with neprilysin inhibition (ARNi) demonstrates efficacy in acute decompensated HF.
• Advanced continuous flow left ventricular assist devices offer improved durability for advanced HF.

Conclusions:

• Emerging treatments including SGLT2 inhibitors, cardiac amyloidosis therapies, iron repletion, ARNi, and novel mechanical support devices are poised to transform HF care.
• These trials represent significant advancements in both the prevention and treatment of heart failure.
• The findings have substantial practical implications for clinical practice and future research directions.